AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in the shape of a new two-drug ...
209.5 x 109.2 cm. (82.5 x 43 in.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback